Increased Safety Concerns Could Reduce Drug Development Pipelines By 20%, IMS Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The pharmaceutical research firm cites increased regulatory scrutiny and post-marketing commitments as catalyst.
You may also be interested in...
Drug Safety Concerns Could Affect Early Review Stages, FDA's Gottlieb Says
The deputy commissioner reiterates that the agency has not become risk averse when it comes to approvals, however.
Drug Safety Concerns Could Affect Early Review Stages, FDA's Gottlieb Says
The deputy commissioner reiterates that the agency has not become risk averse when it comes to approvals, however.
Vioxx Litigation May Freeze Class-Wide Drug Development, AEI Scholar Calfee Suggests
Former FDA Chief Counsel Troy says Merck’s strategy to defend each case independently may backfire.